If you can't get it right the first time, try try again! This one seems a little more based on stock action, mentioning what one smart fund manager is buying, rather than science. However, the author just can't resist getting in a little zinger with these last 2 sentences.
" The drug may also get approved to treat prostate cancer, and the company is looking at treating as many as nine different cancers with it. On the other hand, Cometriq is expensive, and the company's debt has been growing, along with its share count."
This could help move us forward to that trap door wider was talking about at 5.40 by ER time.
The push-pull between the bears and bulls on EXEL continues and unfortunately when we approach a critical juncture (ASCO 2013 and ER) we get a lot of these MF and other worthless articles.
It appears more and more that although cabo may become a huge medical success, EXEL has shot itself in the foot (dilutive financing), and is slowly either bleeding to death or is slowly healing. The key word being "slowly" .
Fast fix is to let MM go. He is not only inadequate at finance, but at regulatory affair as well. All the cabo's good science has been drained by his mistakes. Vote no so they can at least hear our weak disgruntled voice.